Core Insights - ResMed, Inc. is a leading designer, manufacturer, and distributor in the global market for generators, masks, and related accessories for the treatment of sleep-disordered breathing (SDB) and other respiratory disorders [12] - The company has received a 1 (Strong Buy) rating on the Zacks Rank, indicating strong potential for performance [23] - Recent earnings estimates for fiscal 2024 have been revised upwards by five analysts, with the Zacks Consensus Estimate increasing by $0.24 to $7.70 per share, reflecting a positive outlook [13] Zacks Rank and Style Scores - The Zacks Rank utilizes earnings estimate revisions to help investors build successful portfolios, with a focus on stocks rated 1 (Strong Buy) or 2 (Buy) [4][18] - ResMed has a Momentum Style Score of B, with shares increasing by 0.2% over the past four weeks, indicating positive momentum [20] - The VGM Score, which combines Value, Growth, and Momentum Style Scores, rates ResMed as B, further supporting its attractiveness as an investment [26] Investment Strategy - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B to maximize upside potential [18][19] - The Style Scores categorize stocks based on investing styles, helping investors identify securities with the highest chances of outperforming the market [8][22]

Core Insights - ResMed, Inc. (RMD) shares have increased by 16.3% since the last earnings report, significantly outperforming the industry average of 1.3% and the medical sector's rise of 3.6% [1] - The company reported better-than-expected earnings and revenues for the third quarter of fiscal 2024, driven by strong demand for its products and software solutions, resulting in double-digit growth in mask and accessories revenue [2] - ResMed's market capitalization stands at $31.33 billion, and it is recognized as a solid wealth creator for investors, holding a Zacks Rank of 2 (Buy) [1][2] Financial Performance - The company achieved a strong bottom line due to ongoing operational efficiencies, which improved margins and profitability [2] - ResMed paid out $70 million in dividends during the fiscal third quarter and repurchased 261,000 shares for $50 million, indicating robust capital management [8] - The company has a historical cash flow growth rate of 12.82%, outperforming the industry average of 5.98% [8] Growth Strategies - ResMed identified three key growth horizons: enhancing its core sleep apnea and respiratory care business, delivering advanced medical devices and scalable digital health solutions, and innovating advanced software solutions for digital care [4] - The company is ramping up demand-generation initiatives to increase awareness and access to care for sleep suffocation across global markets, leveraging both traditional healthcare channels and social media [5] - The myAir app has seen strong adoption, with 7.8 million users by the end of the fiscal third quarter, contributing to better patient outcomes and increased resupply [6] Market Outlook - Earnings for ResMed are expected to grow by 13.2% over the next five years, with recent estimates reflecting analysts' optimism [10] - The Zacks Consensus Estimate for RMD's earnings in 2024 and 2025 has increased by 2.8% and 4.9%, respectively, in the past 90 days [10]

Core Insights - ResMed supported 26 abstracts presented at the American Thoracic Society International Conference, highlighting the effectiveness of PAP therapy in treating sleep-disordered breathing and its cardiovascular health benefits [1][10] Group 1: PAP Therapy and Sleep Disorders - Studies demonstrated that PAP therapy continues to lower risks associated with sleep disorders, with a meta-study showing a 37% lower mortality rate in patients with PAP-treated obstructive sleep apnea (OSA) compared to untreated OSA [3] - An analysis of 17,000 treatment-naïve patients indicated that PAP treatment reduces hospitalization rates over the first four years of treatment, correlating PAP therapy use with reduced healthcare resource utilization [4] Group 2: Prevalence and Future Trends of OSA - Research projected a 27.6% increase in OSA cases in the U.S. by 2050 among individuals aged 30-70, with an overall prevalence of 26% expected in this demographic due to aging and rising BMI trends [5] - The increasing prevalence of OSA is anticipated to drive higher reliance on PAP therapy, which remains the gold standard for treatment [5] Group 3: GLP-1 Receptor Agonists and PAP Therapy - A study found that the use of GLP-1 receptor agonists did not lead to higher discontinuation rates of PAP therapy; instead, patients adhering to GLP-1 medication had higher levels of PAP therapy use compared to non-adherent patients [2][8] Group 4: Adaptive Servo-Ventilation (ASV) Therapy - Studies on ASV therapy showed reduced symptom burden and improved quality of life for patients with treatment-emergent or persistent central sleep apnea (TE-CSA) [6] - Another study indicated that ASV treatment for patients on long-term opioid therapy resulted in a median reduction in Epworth Sleepiness Scale values, demonstrating lower symptom burden and improved quality of life [7] Group 5: Non-Invasive Ventilation (NIV) in COPD - Research involving nearly 50,000 adults with COPD indicated that long-term home use of NIV is strongly associated with a reduced risk of death [9]

Core Insights - ResMed supported 26 abstracts presented at the American Thoracic Society International Conference, highlighting the effectiveness of PAP therapy in treating sleep-disordered breathing and its cardiovascular health benefits [1][10] Group 1: PAP Therapy and Sleep Disorders - Studies demonstrated that PAP therapy significantly lowers mortality rates, with a 37% reduction in patients with obstructive sleep apnea (OSA) who received treatment compared to those who did not [3] - Research indicated that PAP treatment reduces hospitalization rates in OSA patients over the first four years of treatment, correlating with decreased healthcare resource utilization [4] - The prevalence of OSA in the U.S. is projected to increase by 27.6% by 2050 among individuals aged 30-70, with an expected overall prevalence of 26% in this demographic [5][8] Group 2: GLP-1 Receptor Agonists and PAP Therapy - A study found that the use of GLP-1 receptor agonists did not increase discontinuation rates of PAP therapy; instead, patients adhering to GLP-1 medication showed higher levels of PAP therapy use [2][8] Group 3: Adaptive Servo-Ventilation (ASV) Therapy - ASV therapy was shown to reduce symptom burden and improve quality of life in patients with treatment-emergent or persistent central sleep apnea (TE-CSA) [6] - Another study indicated that ASV treatment in patients on long-term opioid therapy resulted in a median reduction in Epworth Sleepiness Scale values, reflecting lower symptom burden and improved quality of life [7] Group 4: COPD and Non-Invasive Ventilation (NIV) - Long-term home use of non-invasive ventilation (NIV) was associated with a significantly reduced risk of death in nearly 50,000 adults with chronic obstructive pulmonary disease (COPD) [9]

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on ResMed (RMD), and emphasizes the importance of using these recommendations in conjunction with other analytical tools like the Zacks Rank for making informed investment decisions [1][4]. Group 1: Brokerage Recommendations - ResMed has an average brokerage recommendation (ABR) of 1.68, indicating a consensus between Strong Buy and Buy, with 57.1% of recommendations being Strong Buy and 14.3% being Buy [2]. - The article highlights that brokerage analysts tend to exhibit a strong positive bias in their ratings, often issuing five "Strong Buy" recommendations for every "Strong Sell" [5][9]. - The interests of brokerage firms may not align with those of retail investors, leading to potential misguidance in stock price movements [6][9]. Group 2: Zacks Rank - The Zacks Rank, which classifies stocks from 1 (Strong Buy) to 5 (Strong Sell), is presented as a more reliable indicator of near-term price performance compared to ABR [7][10]. - The Zacks Rank is based on earnings estimate revisions, which have shown a strong correlation with stock price movements, making it a timely tool for investors [10][11]. - ResMed currently holds a Zacks Rank 1 (Strong Buy) due to a 2.8% increase in the Zacks Consensus Estimate for the current year, reflecting analysts' growing optimism about the company's earnings prospects [12][13].

ResMed Inc. (RMD) is gaining from the global supply of its cloud-connected platforms, AirSense10 and AirSense11. The MEDIFOX DAN business contributes to the robust organic growth of the SaaS business, raising optimism. However, escalating debt levels and the competitive landscape are a concern. Robust Mask Sales: ResMed continues to see strong demand for its market-leading mask portfolio, gaining from a competitor's recall. The company continues to witness strong growth in the U.S. mask and accessories busi ...

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Complete list of ResMed sponsored studies to be presented at ATS 2024: | | Sunday, May 19, | | --- | --- | | Treatment of sleep-disordered breathing with adaptive servo-ventilation (READ-ASV) in opioid users – a European registry | 2024 | | | 9:15 AM | | | -11:15 AM | | | Sunday | | | May 19, | | 8-year Trends in Obesity, Type 2 Diabetes, and Glucagon-like Peptide-1 (GLP-1) Use in Patients | | | With Obstructive Sleep Apnea | 2024 | | | 9:15 AM - | | | 11:15 AM | ...

Investors might want to bet on ResMed (RMD) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The power of a cha ...

BLOOMINGTON, Minn., May 16, 2024 (GLOBE NEWSWIRE) -- MatrixCare, a leading global technology provider in post-acute care, has partnered with Health Gorilla, the nation's only dual-designated Qualified Health Information Network (QHIN) and Qualified Health Information Organization (QHIO). This strategic alliance enables MatrixCare to seamlessly access, exchange, and integrate comprehensive clinical data into its Electronic Health Record (EHR) platform. Medical providers need an easy and secure way to exchang ...

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with ResMed (RMD) identified as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10]. Group 1: Earnings Growth - ResMed has a historical EPS growth rate of 13.3%, with projected EPS growth of 18.6% for the current year, surpassing the industry average of 13.6% [5]. Group 2: Cash Flow Growth - The year-over-year cash flow growth for ResMed stands at 9.8%, significantly higher than the industry average of -12.5% [6]. - Over the past 3-5 years, ResMed's annualized cash flow growth rate has been 12.8%, compared to the industry average of 6% [7]. Group 3: Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for ResMed, with the Zacks Consensus Estimate for the current year increasing by 2.7% over the past month [9]. Group 4: Overall Positioning - ResMed has achieved a Growth Score of A and holds a Zacks Rank of 2, indicating strong potential for outperformance in the growth stock category [10].